SI3728254T1 - Benzilamino substituirani piridopirimidinoni in derivati kot zaviralci SOS1 - Google Patents
Benzilamino substituirani piridopirimidinoni in derivati kot zaviralci SOS1Info
- Publication number
- SI3728254T1 SI3728254T1 SI201830909T SI201830909T SI3728254T1 SI 3728254 T1 SI3728254 T1 SI 3728254T1 SI 201830909 T SI201830909 T SI 201830909T SI 201830909 T SI201830909 T SI 201830909T SI 3728254 T1 SI3728254 T1 SI 3728254T1
- Authority
- SI
- Slovenia
- Prior art keywords
- derivatives
- pyridopyrimidinones
- benzylamino substituted
- sos1 inhibitors
- sos1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17209865 | 2017-12-21 | ||
| PCT/EP2018/086197 WO2019122129A1 (en) | 2017-12-21 | 2018-12-20 | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| EP18830816.7A EP3728254B1 (en) | 2017-12-21 | 2018-12-20 | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3728254T1 true SI3728254T1 (sl) | 2023-06-30 |
Family
ID=60781991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201830909T SI3728254T1 (sl) | 2017-12-21 | 2018-12-20 | Benzilamino substituirani piridopirimidinoni in derivati kot zaviralci SOS1 |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10829487B2 (sl) |
| EP (2) | EP3728254B1 (sl) |
| JP (1) | JP7189956B2 (sl) |
| KR (1) | KR102746913B1 (sl) |
| CN (1) | CN111372932B (sl) |
| AR (1) | AR114164A1 (sl) |
| AU (1) | AU2018390927B2 (sl) |
| BR (1) | BR112020010123A2 (sl) |
| CA (1) | CA3085835A1 (sl) |
| CL (2) | CL2020001501A1 (sl) |
| CO (1) | CO2020007218A2 (sl) |
| CR (2) | CR20200312A (sl) |
| DK (1) | DK3728254T3 (sl) |
| EA (1) | EA202091491A1 (sl) |
| EC (1) | ECSP20040257A (sl) |
| ES (1) | ES2944306T3 (sl) |
| FI (1) | FI3728254T3 (sl) |
| HR (1) | HRP20230400T1 (sl) |
| HU (1) | HUE062076T2 (sl) |
| IL (1) | IL275379B2 (sl) |
| JO (1) | JOP20200154A1 (sl) |
| LT (1) | LT3728254T (sl) |
| MA (1) | MA51290A (sl) |
| MX (1) | MX2020006438A (sl) |
| PE (1) | PE20210163A1 (sl) |
| PH (1) | PH12020550786A1 (sl) |
| PL (1) | PL3728254T3 (sl) |
| PT (1) | PT3728254T (sl) |
| RS (1) | RS64167B1 (sl) |
| SA (1) | SA520412278B1 (sl) |
| SG (1) | SG11202005881YA (sl) |
| SI (1) | SI3728254T1 (sl) |
| TW (1) | TWI810230B (sl) |
| UA (1) | UA126173C2 (sl) |
| WO (1) | WO2019122129A1 (sl) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3697789T (lt) | 2017-10-18 | 2021-12-10 | Incyte Corporation | Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai |
| HRP20230400T1 (hr) * | 2017-12-21 | 2023-06-23 | Boehringer Ingelheim International Gmbh | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 |
| MA53561A (fr) | 2018-09-05 | 2022-05-11 | Incyte Corp | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) |
| CA3142239A1 (en) | 2019-06-19 | 2020-12-24 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| WO2021074227A1 (en) * | 2019-10-15 | 2021-04-22 | Bayer Aktiengesellschaft | 2-methyl-aza-quinazolines |
| EP4055017A1 (en) * | 2019-11-08 | 2022-09-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| SMT202400273T1 (it) | 2019-11-29 | 2024-09-16 | Lupin Ltd | Composti triciclici sostituiti |
| PH12022551513A1 (en) * | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| CN113045565A (zh) * | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| MX2022008066A (es) | 2019-12-27 | 2022-08-15 | Lupin Ltd | Compuestos triciclicos sustituidos. |
| WO2021173524A1 (en) * | 2020-02-24 | 2021-09-02 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| CN115244058A (zh) * | 2020-04-08 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 |
| PE20240493A1 (es) | 2020-06-02 | 2024-03-15 | Boehringer Ingelheim Int | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer |
| CN113801114B (zh) * | 2020-06-11 | 2022-11-18 | 江苏恒瑞医药股份有限公司 | 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用 |
| WO2021249519A1 (zh) | 2020-06-11 | 2021-12-16 | 江苏恒瑞医药股份有限公司 | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN115942936A (zh) * | 2020-06-24 | 2023-04-07 | 勃林格殷格翰国际有限公司 | 包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法 |
| CN113912608B (zh) * | 2020-07-10 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 |
| CN116234807A (zh) * | 2020-07-24 | 2023-06-06 | 南京明德新药研发有限公司 | 喹唑啉类化合物 |
| TWI793704B (zh) * | 2020-08-06 | 2023-02-21 | 大陸商北京泰德製藥股份有限公司 | Sos1抑制劑、包含其的藥物組合物及其用途 |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer |
| TW202227427A (zh) | 2020-09-16 | 2022-07-16 | 美商拜歐斯瑞克斯公司 | Sos1蛋白降解劑、其醫藥組合物及其治療應用 |
| CN116323623A (zh) * | 2020-09-18 | 2023-06-23 | 拜耳公司 | 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺 |
| CA3196287A1 (en) | 2020-10-20 | 2022-04-28 | Binhua Lv | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof |
| CN114524810B (zh) * | 2020-11-21 | 2023-12-01 | 上海凌达生物医药有限公司 | 一类嘧啶并杂环类化合物、制备方法和用途 |
| US20240051956A1 (en) | 2020-12-22 | 2024-02-15 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| WO2022135590A1 (zh) * | 2020-12-27 | 2022-06-30 | 上海凌达生物医药有限公司 | 一类嘧啶并杂环类化合物、制备方法和用途 |
| WO2022157629A1 (en) * | 2021-01-19 | 2022-07-28 | Lupin Limited | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer |
| CN116546985A (zh) * | 2021-01-28 | 2023-08-04 | 浙江海正药业股份有限公司 | 吡啶并嘧啶类衍生物及其制备方法和用途 |
| WO2022161461A1 (zh) * | 2021-01-29 | 2022-08-04 | 江苏先声药业有限公司 | Sos1抑制剂及其制备方法和应用 |
| CN114436976B (zh) * | 2021-01-29 | 2023-07-11 | 石药集团中奇制药技术（石家庄）有限公司 | 一种新型喹唑啉类衍生物及其制备和应用 |
| CN114835719A (zh) * | 2021-02-01 | 2022-08-02 | 苏州泽璟生物制药股份有限公司 | 取代双环并芳杂环胺类抑制剂及其制备方法和应用 |
| CN114835703A (zh) * | 2021-02-02 | 2022-08-02 | 苏州泽璟生物制药股份有限公司 | 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用 |
| IL305046A (en) | 2021-02-08 | 2023-10-01 | Wuhan Humanwell Innovative Drug Res And Development Center Limited Company | Pyridopyrimidinone derivative, the method of preparation thereof and its use |
| CN116669738A (zh) * | 2021-02-09 | 2023-08-29 | 苏州阿尔脉生物科技有限公司 | 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途 |
| CN113200981A (zh) * | 2021-02-10 | 2021-08-03 | 杭州英创医药科技有限公司 | 作为sos1抑制剂的杂环化合物 |
| WO2022171118A1 (zh) * | 2021-02-10 | 2022-08-18 | 石药集团中奇制药技术（石家庄）有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| WO2022187411A1 (en) | 2021-03-02 | 2022-09-09 | Kumquat Biosciences Inc. | Heterocycles and uses thereof |
| CN117062818A (zh) * | 2021-03-05 | 2023-11-14 | 南京再明医药有限公司 | 新型sos1抑制剂及其制备方法和应用 |
| AU2022244957A1 (en) | 2021-03-26 | 2023-11-09 | Medshine Discovery Inc. | 6-carbamate substituted heteroaryl ring derivatives |
| WO2022207673A1 (en) | 2021-03-31 | 2022-10-06 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
| WO2022212546A1 (en) * | 2021-03-31 | 2022-10-06 | Acerand Therapeutics (Usa) Limited | Pyridopyrimidinone compounds |
| GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
| TW202304452A (zh) * | 2021-04-09 | 2023-02-01 | 美商銳新醫藥公司 | Ｓｏｓ１抑制劑與ｒａｓ抑制劑於治療癌症之用途 |
| CN117479942A (zh) | 2021-04-09 | 2024-01-30 | 勃林格殷格翰国际有限公司 | 抗癌疗法 |
| MX2023012060A (es) | 2021-04-13 | 2024-01-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr. |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| TWI807787B (zh) * | 2021-04-19 | 2023-07-01 | 大陸商昆藥集團股份有限公司 | 苯並嘧啶三環衍生物及製備方法和應用 |
| EP4328219A4 (en) * | 2021-04-23 | 2024-11-27 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | SOS1 DEGRADING AGENT, ITS PREPARATION PROCESS AND ITS USE |
| JPWO2023008462A1 (sl) | 2021-07-27 | 2023-02-02 | ||
| EP4375284A1 (en) | 2021-08-03 | 2024-05-29 | Evopoint Biosciences Co., Ltd. | Fused ring compound, pharmaceutical composition, and application thereof |
| CN118119600A (zh) * | 2021-08-17 | 2024-05-31 | 治纳辅医药科技有限公司 | Sos1抑制剂及其用途 |
| WO2023030215A1 (zh) * | 2021-08-30 | 2023-03-09 | 浙江海正药业股份有限公司 | 吡啶并嘧啶酮类衍生物及其制备方法和用途 |
| WO2023029833A1 (zh) * | 2021-09-02 | 2023-03-09 | 上海海和药物研究开发股份有限公司 | 一种sos1抑制剂、其制备方法及用途 |
| CN115246841B (zh) * | 2021-09-14 | 2024-02-09 | 北京福元医药股份有限公司 | 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途 |
| CN117957226A (zh) | 2021-09-17 | 2024-04-30 | 南京再明医药有限公司 | 作为sos1抑制剂的杂环化合物及其用途 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115724844B (zh) * | 2021-11-22 | 2024-10-18 | 石药集团中奇制药技术（石家庄）有限公司 | 一种具有抗肿瘤活性的杂环化合物及其用途 |
| JP2024542692A (ja) | 2021-12-01 | 2024-11-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 環化２－アミノ－３－シアノチオフェンを含むｋｒａ分解化合物 |
| EP4441056A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118574836A (zh) | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-胺基-3-氰基噻吩及衍生物 |
| WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| PE20241356A1 (es) | 2021-12-01 | 2024-07-03 | Boehringer Ingelheim Int | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer |
| KR20240122545A (ko) * | 2021-12-17 | 2024-08-12 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 항종양 활성을 갖는 헤테로고리 화합물 및 그 용도 |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| WO2023125737A1 (en) * | 2021-12-29 | 2023-07-06 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds and use thereof |
| EP4463454A1 (en) | 2022-01-14 | 2024-11-20 | Jazz Pharmaceuticals Ireland Limited | Novel amine-substituted phthalazines and derivatives as sos1 inhibitors |
| WO2023138526A1 (zh) * | 2022-01-21 | 2023-07-27 | 南京明德新药研发有限公司 | 含烯丙基的甲基吡啶并嘧啶化合物的晶型 |
| WO2023143147A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海优理惠生医药有限公司 | 一种哒嗪并吡啶酮类化合物、其药物组合物及应用 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| GB202203976D0 (en) | 2022-03-22 | 2022-05-04 | Jazz Pharmaceuticals Ireland Ltd | Tricyclic phthalazines and derivatives as sos1 inhibitors |
| CN119095849A (zh) | 2022-04-20 | 2024-12-06 | 金橘生物科技公司 | 大环杂环及其用途 |
| WO2023215257A2 (en) * | 2022-05-03 | 2023-11-09 | Revolution Medicines, Inc. | Sos1 inhibitors and uses thereof |
| WO2023215256A1 (en) * | 2022-05-03 | 2023-11-09 | Revolution Medicines, Inc. | Sos1 inhibitors and uses thereof |
| AU2023276599A1 (en) | 2022-05-25 | 2024-12-05 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| CN119384422A (zh) * | 2022-07-01 | 2025-01-28 | 四川汇宇制药股份有限公司 | 哒嗪并吡啶酮衍生物及其用途 |
| TW202404605A (zh) * | 2022-07-07 | 2024-02-01 | 大陸商武漢人福創新藥物研發中心有限公司 | 包含ｓｏｓ１抑制劑的藥物組成物 |
| CN115057847B (zh) * | 2022-07-26 | 2024-01-26 | 山东百启生物医药有限公司 | 一种4,6-二氯-5-(1,3-二氧戊环-2-基)-2-甲基嘧啶的制备方法 |
| CN119451960A (zh) * | 2022-08-05 | 2025-02-14 | 上海艾力斯医药科技股份有限公司 | 一种稠环化合物、其制备方法及其应用 |
| CN117534667A (zh) | 2022-08-08 | 2024-02-09 | 武汉人福创新药物研发中心有限公司 | 吡啶并嘧啶酮化合物的晶型、其酸式盐、其酸式盐的晶型和用途 |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024056782A1 (en) | 2022-09-16 | 2024-03-21 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
| WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
| WO2024079252A1 (en) | 2022-10-13 | 2024-04-18 | Bayer Aktiengesellschaft | Sos1 inhibitors |
| WO2024172632A1 (ko) * | 2023-02-16 | 2024-08-22 | (주) 사이러스테라퓨틱스 | Sos1 억제제로서의 아졸릴피리딘 피리다지논 아미드 |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| US20250019385A1 (en) | 2023-05-30 | 2025-01-16 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| GB2631397A (en) | 2023-06-28 | 2025-01-08 | Sevenless Therapeutics Ltd | New treatments for pain |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US6174899B1 (en) | 1998-05-14 | 2001-01-16 | Morton Shulman | Orally administered analgesic composition comprising myfadol |
| CA2680775A1 (en) | 2007-03-23 | 2008-10-02 | F. Hoffmann-La Roche Ag | Aza-pyridopyrimidinone derivatives |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| US8383635B2 (en) * | 2008-08-12 | 2013-02-26 | Glaxosmithkline Llc | Chemical compounds |
| BRPI0924107A2 (pt) | 2008-11-28 | 2019-09-24 | Novartis Ag | inibidores de hsp90 para tratamento terapêutico |
| CN102227226B (zh) | 2008-12-12 | 2015-05-13 | 贝林格尔.英格海姆国际有限公司 | 抗igf抗体 |
| SG10201407012XA (en) | 2009-10-29 | 2014-11-27 | Genosco | Kinase inhibitors |
| EP2649016B1 (en) | 2010-12-06 | 2020-06-10 | Pall Corporation | Continuous processing methods for biological products |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| MA37405A1 (fr) | 2012-03-14 | 2016-03-31 | Lupin Ltd | Composés hétérocyclyle |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP3401314B1 (en) | 2013-03-15 | 2023-11-08 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| JP6333380B2 (ja) * | 2013-08-19 | 2018-05-30 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 可能性を秘めた抗がん剤として有用な３−（４−エチニルフェニル）ピリドピリミジノン化合物及びその調製方法 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016077793A1 (en) | 2014-11-14 | 2016-05-19 | Children's Hospital Medical Center | Sos1 inhibitors for cancer treatment |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| HRP20230400T1 (hr) * | 2017-12-21 | 2023-06-23 | Boehringer Ingelheim International Gmbh | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 |
| CA3142239A1 (en) | 2019-06-19 | 2020-12-24 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
-
2018
- 2018-12-20 HR HRP20230400TT patent/HRP20230400T1/hr unknown
- 2018-12-20 BR BR112020010123-0A patent/BR112020010123A2/pt unknown
- 2018-12-20 AR ARP180103772A patent/AR114164A1/es unknown
- 2018-12-20 SG SG11202005881YA patent/SG11202005881YA/en unknown
- 2018-12-20 CR CR20200312A patent/CR20200312A/es unknown
- 2018-12-20 MX MX2020006438A patent/MX2020006438A/es unknown
- 2018-12-20 ES ES18830816T patent/ES2944306T3/es active Active
- 2018-12-20 FI FIEP18830816.7T patent/FI3728254T3/fi active
- 2018-12-20 KR KR1020207017298A patent/KR102746913B1/ko active IP Right Grant
- 2018-12-20 TW TW107146126A patent/TWI810230B/zh active
- 2018-12-20 PL PL18830816.7T patent/PL3728254T3/pl unknown
- 2018-12-20 CR CR20210307A patent/CR20210307A/es unknown
- 2018-12-20 DK DK18830816.7T patent/DK3728254T3/da active
- 2018-12-20 PE PE2020000811A patent/PE20210163A1/es unknown
- 2018-12-20 PH PH1/2020/550786A patent/PH12020550786A1/en unknown
- 2018-12-20 CN CN201880075128.0A patent/CN111372932B/zh active Active
- 2018-12-20 AU AU2018390927A patent/AU2018390927B2/en active Active
- 2018-12-20 SI SI201830909T patent/SI3728254T1/sl unknown
- 2018-12-20 MA MA051290A patent/MA51290A/fr unknown
- 2018-12-20 UA UAA202004415A patent/UA126173C2/uk unknown
- 2018-12-20 EP EP18830816.7A patent/EP3728254B1/en active Active
- 2018-12-20 EA EA202091491A patent/EA202091491A1/ru unknown
- 2018-12-20 EP EP23156525.0A patent/EP4219493A1/en active Pending
- 2018-12-20 CA CA3085835A patent/CA3085835A1/en active Pending
- 2018-12-20 JO JOP/2020/0154A patent/JOP20200154A1/ar unknown
- 2018-12-20 PT PT188308167T patent/PT3728254T/pt unknown
- 2018-12-20 RS RS20230333A patent/RS64167B1/sr unknown
- 2018-12-20 LT LTEPPCT/EP2018/086197T patent/LT3728254T/lt unknown
- 2018-12-20 JP JP2020533742A patent/JP7189956B2/ja active Active
- 2018-12-20 HU HUE18830816A patent/HUE062076T2/hu unknown
- 2018-12-20 WO PCT/EP2018/086197 patent/WO2019122129A1/en active Application Filing
- 2018-12-20 US US16/226,824 patent/US10829487B2/en active Active
-
2020
- 2020-06-05 CL CL2020001501A patent/CL2020001501A1/es unknown
- 2020-06-12 CO CONC2020/0007218A patent/CO2020007218A2/es unknown
- 2020-06-15 IL IL275379A patent/IL275379B2/en unknown
- 2020-06-19 SA SA520412278A patent/SA520412278B1/ar unknown
- 2020-07-16 EC ECSENADI202040257A patent/ECSP20040257A/es unknown
- 2020-09-24 US US17/030,603 patent/US11814380B2/en active Active
-
2021
- 2021-04-13 CL CL2021000907A patent/CL2021000907A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275379A (en) | Benzylamino-converted pyridopyrimidinones and novel antecedents as SOS1 inhibitors | |
| IL278916A (en) | Benzoimidazole derivatives as PAD4 inhibitors | |
| ZA201905811B (en) | Novel inhibitors | |
| IL261167A (en) | Heteroaryl pad4 inhibitors | |
| IL261170B (en) | Carboxamide history used as rsk inhibitors | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| IL259796A (en) | Aza-benzimidazole inhibitors of pad4 | |
| IL280641A (en) | Converted benzimidazoles as PAD4 inhibitors | |
| HK1250926A1 (zh) | 抑制劑及其應用 | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL257283A (en) | Chiral phosphoramidates and their history | |
| HK1248209A1 (zh) | 尿素衍生物和其用途 | |
| HK1250161B (zh) | 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 | |
| PT3724196T (pt) | Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| HK1248208A1 (zh) | 尿素衍生物和其用途 | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201404330D0 (en) | Selective glycosidase inhibitors and uses thereof | |
| GB201404332D0 (en) | Selective glycosidase inhibitors and uses thereof |